Atopic DermatitisImmuneSkinBankNCT06599411
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
An observational study of Atopic Dermatitis and Psoriasis, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
Trial summary
Chronic inflammatory skin diseases constitute a heterogeneous group of pathologies. They affect the skin but also other organs (joints, lungs, muscles, etc.). Their prognosis and response to treatments is extremely variable. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa
- What is being tested?
- Sampling
- How many people
- 830 participants
- Where
- 1 siteFrance
- Study dates
- 20 Oct 2025to 20 Oct 2045
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients affected by inflammatory skin disease and controls
Who may be able to join
- Patients:
- Age>18 years
- Informed consent signed by the patient
- Diagnosis of moderate to severe chronic inflammatory skin disease (IGA score 3 or 4) including: atopic dermatitis, psoriasis, hidradenitis suppurativa, lichen planus, cutaneous lupus, dermatomyositis, cutaneous scleroderma (=morphea), neutrophilic dermatosis, cutaneous granulomatosis, cutaneaous vasculitis, autoimmune bullous dermatosis
- Or diagnosis of active leprosy (tuberculoid, lepromatous, reversion type 1, reversion type 2, hypersensitivity type 3), excluding pure neurological leprosy. Classification into 5 stages according to the Ridley and Jopling classification [1], Reversion reaction (type 1 reaction) and leprous erythema nodosum (type 2 reaction).
- Healthy controls :
Show all 10Show fewer
- Age>18 years
- Plastic surgery patients who have had any type of surgery resulting in healthy skin remnants
- Informed consent signed by the patient
- Absence of known cutaneous inflammatory disease.
Who cannot join
- Under guardianship or curatorship
- Pregnant or breastfeeding woman
- Lack of affiliation with a social security system
- Current systemic treatment with immunosupressant (including corticosteroid therapy) or an immunomodulator or received within the last 3 months.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Hôpital Saint Louis
Paris
Charles Cassius, MD phD, 1 42 49 99 61 ext. +33, charles.cassius@aphp.fr
About this study
Official title: Identification Des Marqueurs Biologiques cutanés et Sanguins prédictifs de réponse Aux Traitements systémiques au Cours Des Maladies cutanées Inflammatoires Chroniques
Chronic inflammatory skin diseases constitute a heterogeneous group of pathologies. They affect the skin but also other organs (joints, lungs, muscles, etc.). Their prognosis and response to treatments is extremely variable. The discovery of prognosis factors will help to precisely guide the treatment regimen and its intensification based on individual markers. The identification of new therapeutic targets is essential to develop new innovative treatments for inflammatory skin diseases.
The main objective is to identify new cellular or molecular prognostic factors associated with treatment response at 1 year in inflammatory skin diseases.
The secondary objectives are a better understanding of the pathophysiology of chronic inflammatory skin diseases, the identification of new cellular, molecular and microbiological prognostic factors associated with the clinical state after 10 years of evolution and the identification of prognostic markers of drug toxicity.
- Conditions
- Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Lichen Planus, Cutaneous Lupus, Dermatomyositis
- Being tested
- Sampling
- Medical subject headings
- Dermatitis, Atopic, Psoriasis, Hidradenitis Suppurativa, Lichen Planus, Dermatomyositis, Skin Diseases, Vascular
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SamplingOther
Collection of an additional volume of blood, Superficial skin biopsy, Skin swab, Hair follicle, Stool,
SamplingOther
Collection of an additional volume of blood, Preservation of post-operative skin remnants, Skin swab, Hair follicle, Stool
| Study group | Role | What they receive |
|---|---|---|
| Patients | Affected by inflammatory skin disease Receives: Other: Sampling | |
| Controls | Plastic surgery patients who have had any type of surgery resulting in healthy skin remnants Receives: Other: Sampling |
What is being measured
The primary outcome is the main question the study is designed to answer.
Therapeutic response
It is defined as complete or partial remission on the Investigator/Physician Global Assessment (IGA/PGA) scale.
Measured: At 1 year
Secondary outcomes (44)
Expression of markers of blood and skin immunological signaling pathways
Mainly Th1, Th2, Th9, Th17, Th22 and Treg
Measured: At inclusion
Expression of markers of blood and skin immunological signaling pathways
Mainly Th1, Th2, Th9, Th17, Th22 and Treg
Measured: At 4 months
Expression of markers of blood and skin immunological signaling pathways
Mainly Th1, Th2, Th9, Th17, Th22 and Treg
Measured: At 1 year
Expression of markers of blood T cell populations and skin transcriptomics
Measured: At inclusion
Expression of markers of blood T cell populations and skin transcriptomics
Measured: At 4 months
Expression of markers of blood T cell populations and skin transcriptomics
Measured: At 1 year
Therapeutic response
Based on markers of blood T cell populations and skin transcriptomics
Measured: At inclusion
Therapeutic response
Based on markers of blood T cell populations and skin transcriptomics
Measured: At 4 months
Therapeutic response
Based on markers of blood T cell populations and skin transcriptomics
Measured: At 1 year
Therapeutic response
Based on markers of blood T cell populations and skin transcriptomics
Measured: At 2 years
Therapeutic response
Based on markers of blood T cell populations and skin transcriptomics
Measured: At 3 years
Therapeutic response
Based on markers of blood T cell populations and skin transcriptomics
Measured: At 4 years
Therapeutic response
Based on markers of blood T cell populations and skin transcriptomics
Measured: At 5 years
Therapeutic response
Based on markers of blood T cell populations and skin transcriptomics
Measured: At 6 years
Therapeutic response
Based on markers of blood T cell populations and skin transcriptomics
Measured: At 7 years
Therapeutic response
Based on markers of blood T cell populations and skin transcriptomics
Measured: At 8 years
Therapeutic response
Based on markers of blood T cell populations and skin transcriptomics
Measured: At 9 years
Therapeutic response
Based on markers of blood T cell populations and skin transcriptomics
Measured: At 10 years
Microbiota markers
Identification of cluster specific to the pathology, identification of an over-representation of one or more microbiological species.
For patients and controls
Measured: At inclusion
Microbiota markers
Identification of cluster specific to the pathology, identification of an over-representation of one or more microbiological species.
For patients only
Measured: At 1 year
Proportion of patients suffering from adverse effects of systemic treatments
According to the CTCAE classification and MedDRA
Measured: At inclusion
Proportion of patients suffering from adverse effects of systemic treatments
According to the CTCAE classification and MedDRA
Measured: At 4 months
Proportion of patients suffering from adverse effects of systemic treatments
According to the CTCAE classification and MedDRA
Measured: At 1 year
Proportion of patients suffering from adverse effects of systemic treatments
According to the CTCAE classification and MedDRA
Measured: At 2 years
Proportion of patients suffering from adverse effects of systemic treatments
According to the CTCAE classification and MedDRA
Measured: At 3 years
Proportion of patients suffering from adverse effects of systemic treatments
According to the CTCAE classification and MedDRA
Measured: At 4 years
Proportion of patients suffering from adverse effects of systemic treatments
According to the CTCAE classification and MedDRA
Measured: At 5 years
Proportion of patients suffering from adverse effects of systemic treatments
According to the CTCAE classification and MedDRA
Measured: At 6 years
Proportion of patients suffering from adverse effects of systemic treatments
According to the CTCAE classification and MedDRA
Measured: At 7 years
Proportion of patients suffering from adverse effects of systemic treatments
According to the CTCAE classification and MedDRA
Measured: At 8 years
Proportion of patients suffering from adverse effects of systemic treatments
According to the CTCAE classification and MedDRA
Measured: At 9 years
Proportion of patients suffering from adverse effects of systemic treatments
According to the CTCAE classification and MedDRA
Measured: At 10 years
Quality of life measurement
The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability.
The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life.
The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life.
Measured: At inclusion
Quality of life measurement
The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability.
The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life.
The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life.
Measured: At 4 months
Quality of life measurement
The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability.
The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life.
The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life.
Measured: At 1 year
Quality of life measurement
The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability.
The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life.
The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life.
Measured: At 2 years
Quality of life measurement
The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability.
The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life.
The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life.
Measured: At 3 years
Quality of life measurement
The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability.
The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life.
The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life.
Measured: At 4 years
Quality of life measurement
The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability.
The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life.
The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life.
Measured: At 5 years
Quality of life measurement
The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability.
The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life.
The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life.
Measured: At 6 years
Quality of life measurement
The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability.
The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life.
The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life.
Measured: At 7 years
Quality of life measurement
The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability.
The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life.
The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life.
Measured: At 8 years
Quality of life measurement
The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability.
The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life.
The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life.
Measured: At 9 years
Quality of life measurement
The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability.
The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life.
The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life.
Measured: At 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2024
- Study start20 Oct 2025
- Primary completion20 Nov 2035 (estimated)
- Study completion20 Oct 2045 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atopic DermatitisStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 830 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06599411
- Sponsor's protocol ID
- APHP240183
- Acronym
- ImmuneSkinBank
- Status last verified
- Jun 2026
- First submitted
- 13 Sep 2024
- Last updated
- 12 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 12 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Identification Des Marqueurs Biologiques cutanés et Sanguins prédictifs de réponse Aux Traitements systémiques au Cours Des Maladies cutanées Inflammatoires Chroniques
- ClinicalTrials.gov ID
- NCT06599411
- Acronym / sponsor ID
- ImmuneSkinBank / APHP240183
- Conditions
- Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Lichen Planus, Cutaneous Lupus, Dermatomyositis
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 830 participants (estimated)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Study start
- 20 Oct 2025 (actual)
- Primary completion
- 20 Nov 2035 (estimated)
- Study completion
- 20 Oct 2045 (estimated)
- First posted
- 19 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chronic inflammatory skin diseases constitute a heterogeneous group of pathologies. They affect the skin but also other organs (joints, lungs, muscles, etc.). Their prognosis and response to treatments is extremely variable. The discovery of prognosis factors will help to precisely guide the treatment regimen and its intensification based on individual markers. The identification of new therapeutic targets is essential to develop new innovative treatments for inflammatory skin diseases.
The main objective is to identify new cellular or molecular prognostic factors associated with treatment response at 1 year in inflammatory skin diseases.
The secondary objectives are a better understanding of the pathophysiology of chronic inflammatory skin diseases, the identification of new cellular, molecular and microbiological prognostic factors associated with the clinical state after 10 years of evolution and the identification of prognostic markers of drug toxicity.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients | – | Other: SamplingAffected by inflammatory skin disease |
| Controls | – | Other: SamplingPlastic surgery patients who have had any type of surgery resulting in healthy skin remnants |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients affected by inflammatory skin disease and controls
Key inclusion criteria (10 listed)
- Age>18 years
- Informed consent signed by the patient
- Diagnosis of moderate to severe chronic inflammatory skin disease (IGA score 3 or 4) including: atopic dermatitis, psoriasis, hidradenitis suppurativa, lichen planus, cutaneous lupus, dermatomyositis, cutaneous scleroderma (=morphea), neutrophilic dermatosis, cutaneous granulomatosis, cutaneaous vasculitis, autoimmune bullous dermatosis
- Or diagnosis of active leprosy (tuberculoid, lepromatous, reversion type 1, reversion type 2, hypersensitivity type 3), excluding pure neurological leprosy. Classification into 5 stages according to the Ridley and Jopling classification [1], Reversion reaction (type 1 reaction) and leprous erythema nodosum (type 2 reaction).
- Age>18 years
Key exclusion criteria (4 listed)
- Under guardianship or curatorship
- Pregnant or breastfeeding woman
- Lack of affiliation with a social security system
- Current systemic treatment with immunosupressant (including corticosteroid therapy) or an immunomodulator or received within the last 3 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SamplingCollection of an additional volume of blood, Superficial skin biopsy, Skin swab, Hair follicle, Stool, | Other | Patients |
| SamplingCollection of an additional volume of blood, Preservation of post-operative skin remnants, Skin swab, Hair follicle, Stool | Other | Controls |
Primary outcome
Therapeutic response
Time frame: At 1 year
It is defined as complete or partial remission on the Investigator/Physician Global Assessment (IGA/PGA) scale.
44 secondary outcomes
Expression of markers of blood and skin immunological signaling pathways
Time frame: At inclusion
Expression of markers of blood and skin immunological signaling pathways
Time frame: At 4 months
Expression of markers of blood and skin immunological signaling pathways
Time frame: At 1 year
Expression of markers of blood T cell populations and skin transcriptomics
Time frame: At inclusion
Expression of markers of blood T cell populations and skin transcriptomics
Time frame: At 4 months
Expression of markers of blood T cell populations and skin transcriptomics
Time frame: At 1 year
Therapeutic response
Time frame: At inclusion
Therapeutic response
Time frame: At 4 months
Therapeutic response
Time frame: At 1 year
Therapeutic response
Time frame: At 2 years
Therapeutic response
Time frame: At 3 years
Therapeutic response
Time frame: At 4 years
Therapeutic response
Time frame: At 5 years
Therapeutic response
Time frame: At 6 years
Therapeutic response
Time frame: At 7 years
Therapeutic response
Time frame: At 8 years
Therapeutic response
Time frame: At 9 years
Therapeutic response
Time frame: At 10 years
Microbiota markers
Time frame: At inclusion
Microbiota markers
Time frame: At 1 year
Proportion of patients suffering from adverse effects of systemic treatments
Time frame: At inclusion
Proportion of patients suffering from adverse effects of systemic treatments
Time frame: At 4 months
Proportion of patients suffering from adverse effects of systemic treatments
Time frame: At 1 year
Proportion of patients suffering from adverse effects of systemic treatments
Time frame: At 2 years
Proportion of patients suffering from adverse effects of systemic treatments
Time frame: At 3 years
Proportion of patients suffering from adverse effects of systemic treatments
Time frame: At 4 years
Proportion of patients suffering from adverse effects of systemic treatments
Time frame: At 5 years
Proportion of patients suffering from adverse effects of systemic treatments
Time frame: At 6 years
Proportion of patients suffering from adverse effects of systemic treatments
Time frame: At 7 years
Proportion of patients suffering from adverse effects of systemic treatments
Time frame: At 8 years
Proportion of patients suffering from adverse effects of systemic treatments
Time frame: At 9 years
Proportion of patients suffering from adverse effects of systemic treatments
Time frame: At 10 years
Quality of life measurement
Time frame: At inclusion
Quality of life measurement
Time frame: At 4 months
Quality of life measurement
Time frame: At 1 year
Quality of life measurement
Time frame: At 2 years
Quality of life measurement
Time frame: At 3 years
Quality of life measurement
Time frame: At 4 years
Quality of life measurement
Time frame: At 5 years
Quality of life measurement
Time frame: At 6 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jun 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Atopic Dermatitis
RecruitingPhase 2
Effects of Treatments on Atopic Dermatitis
Eczema, Dermatitis
Enrolling by invitationPhase 3
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis, Eczema
Active, not recruitingPhase 2
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
Atopic Dermatitis
RecruitingPhase 1
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome
RecruitingPhase 2
Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis (AD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Atopic Dermatitis and Psoriasis, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Charles Cassius, MD (630944832 ext. +33, charles.cassius@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Therapeutic response (time frame: At 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2026; AzTrials last refreshed its copy on 26 Oct 2026.